Bridgewater, N.J.-based Cordis is targeted toward “less invasive” treatments for vascular disease, according to the report.
Johnson & Johnson is in the process of removing slower-growth businesses with the ultimate goal of reducing annual costs by $1 billion, according to the report.
The report projects the Cordis sale could bring in between $1.5 billion and $2 billion.
More articles on acquisitions:
Covidien acquires medical device firm Sapheon
Premier to acquire Aperek for $48.5M
5 recent device, biotech company acquisitions
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
